PARP inhibition prevents escape from a telomere-driven crisis and inhibits cell immortalisation

Greg Ngo, Sam Hyatt, Julia Grimstead, Rhiannon Jones, Eric Hendrickson, Chris Pepper, Duncan Baird

Research output: Contribution to journalArticle

Abstract

Telomeric crisis is the final replicative barrier to cell immortalisation; it is characterised by genome instability and cell death and is triggered when telomeres become critically short and are subjected to fusion. Pre-cancerous lesions, or early stage cancers, often show signs of a telomere crisis, suggesting that escape from telomere crisis is a prerequisite for disease progression. Telomeric crisis therefore represents an attractive, and as yet unexplored, opportunity for therapeutic intervention. Here, we show that two clinically approved PARP inhibitors, selectively eliminate human cells undergoing a telomere-driven crisis. Clonal populations of a colorectal cancer cell line (HCT116), or the plasma cell leukaemia cell line (JJN- 3), expressing a dominant-negative telomerase, entered a telomere-driven crisis at defined population doubling points and telomere lengths. The addition of the PARP inhibitors, olaparib or rucaparib prevented these cells from escaping crisis. PARP inhibition did not alter cellular proliferation prior to crisis, rates of telomere erosion or the telomere length at which crisis was initiated, but affected repair of eroded telomeres, resulting in an increased in intra-chromosomal telomere fusion. This was accompanied by enhanced DNA damage checkpoint activation and elevated levels of apoptosis. We propose that PARP inhibitors impair the repair of dysfunctional telomeres and/or induce replicative stress at telomeres to inhibit escape from a telomere crisis. This is the first demonstration that a drug can selectively kill cells experiencing telomeric crisis. We propose that this type of drug, which we term 'crisolytic', has the potential to eliminate pre-cancerous lesions and tumours exhibiting short dysfunctional telomeres.

Original languageEnglish (US)
Pages (from-to)37549-37563
Number of pages15
JournalOncotarget
Volume9
Issue number101
StatePublished - Dec 1 2018

Fingerprint

Telomere
Plasma Cell Leukemia
Cell Line
Genomic Instability
Telomerase
Pharmaceutical Preparations
Population
DNA Damage
Disease Progression
Colorectal Neoplasms
Neoplasms
Cell Death

Keywords

  • Cancer
  • Crisis
  • Genome instability
  • PARP1
  • Telomere

Cite this

Ngo, G., Hyatt, S., Grimstead, J., Jones, R., Hendrickson, E., Pepper, C., & Baird, D. (2018). PARP inhibition prevents escape from a telomere-driven crisis and inhibits cell immortalisation. Oncotarget, 9(101), 37549-37563.

PARP inhibition prevents escape from a telomere-driven crisis and inhibits cell immortalisation. / Ngo, Greg; Hyatt, Sam; Grimstead, Julia; Jones, Rhiannon; Hendrickson, Eric; Pepper, Chris; Baird, Duncan.

In: Oncotarget, Vol. 9, No. 101, 01.12.2018, p. 37549-37563.

Research output: Contribution to journalArticle

Ngo, G, Hyatt, S, Grimstead, J, Jones, R, Hendrickson, E, Pepper, C & Baird, D 2018, 'PARP inhibition prevents escape from a telomere-driven crisis and inhibits cell immortalisation', Oncotarget, vol. 9, no. 101, pp. 37549-37563.
Ngo G, Hyatt S, Grimstead J, Jones R, Hendrickson E, Pepper C et al. PARP inhibition prevents escape from a telomere-driven crisis and inhibits cell immortalisation. Oncotarget. 2018 Dec 1;9(101):37549-37563.
Ngo, Greg ; Hyatt, Sam ; Grimstead, Julia ; Jones, Rhiannon ; Hendrickson, Eric ; Pepper, Chris ; Baird, Duncan. / PARP inhibition prevents escape from a telomere-driven crisis and inhibits cell immortalisation. In: Oncotarget. 2018 ; Vol. 9, No. 101. pp. 37549-37563.
@article{32b7dda901f34d748683ac1bd7913eea,
title = "PARP inhibition prevents escape from a telomere-driven crisis and inhibits cell immortalisation",
abstract = "Telomeric crisis is the final replicative barrier to cell immortalisation; it is characterised by genome instability and cell death and is triggered when telomeres become critically short and are subjected to fusion. Pre-cancerous lesions, or early stage cancers, often show signs of a telomere crisis, suggesting that escape from telomere crisis is a prerequisite for disease progression. Telomeric crisis therefore represents an attractive, and as yet unexplored, opportunity for therapeutic intervention. Here, we show that two clinically approved PARP inhibitors, selectively eliminate human cells undergoing a telomere-driven crisis. Clonal populations of a colorectal cancer cell line (HCT116), or the plasma cell leukaemia cell line (JJN- 3), expressing a dominant-negative telomerase, entered a telomere-driven crisis at defined population doubling points and telomere lengths. The addition of the PARP inhibitors, olaparib or rucaparib prevented these cells from escaping crisis. PARP inhibition did not alter cellular proliferation prior to crisis, rates of telomere erosion or the telomere length at which crisis was initiated, but affected repair of eroded telomeres, resulting in an increased in intra-chromosomal telomere fusion. This was accompanied by enhanced DNA damage checkpoint activation and elevated levels of apoptosis. We propose that PARP inhibitors impair the repair of dysfunctional telomeres and/or induce replicative stress at telomeres to inhibit escape from a telomere crisis. This is the first demonstration that a drug can selectively kill cells experiencing telomeric crisis. We propose that this type of drug, which we term 'crisolytic', has the potential to eliminate pre-cancerous lesions and tumours exhibiting short dysfunctional telomeres.",
keywords = "Cancer, Crisis, Genome instability, PARP1, Telomere",
author = "Greg Ngo and Sam Hyatt and Julia Grimstead and Rhiannon Jones and Eric Hendrickson and Chris Pepper and Duncan Baird",
year = "2018",
month = "12",
day = "1",
language = "English (US)",
volume = "9",
pages = "37549--37563",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "101",

}

TY - JOUR

T1 - PARP inhibition prevents escape from a telomere-driven crisis and inhibits cell immortalisation

AU - Ngo, Greg

AU - Hyatt, Sam

AU - Grimstead, Julia

AU - Jones, Rhiannon

AU - Hendrickson, Eric

AU - Pepper, Chris

AU - Baird, Duncan

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Telomeric crisis is the final replicative barrier to cell immortalisation; it is characterised by genome instability and cell death and is triggered when telomeres become critically short and are subjected to fusion. Pre-cancerous lesions, or early stage cancers, often show signs of a telomere crisis, suggesting that escape from telomere crisis is a prerequisite for disease progression. Telomeric crisis therefore represents an attractive, and as yet unexplored, opportunity for therapeutic intervention. Here, we show that two clinically approved PARP inhibitors, selectively eliminate human cells undergoing a telomere-driven crisis. Clonal populations of a colorectal cancer cell line (HCT116), or the plasma cell leukaemia cell line (JJN- 3), expressing a dominant-negative telomerase, entered a telomere-driven crisis at defined population doubling points and telomere lengths. The addition of the PARP inhibitors, olaparib or rucaparib prevented these cells from escaping crisis. PARP inhibition did not alter cellular proliferation prior to crisis, rates of telomere erosion or the telomere length at which crisis was initiated, but affected repair of eroded telomeres, resulting in an increased in intra-chromosomal telomere fusion. This was accompanied by enhanced DNA damage checkpoint activation and elevated levels of apoptosis. We propose that PARP inhibitors impair the repair of dysfunctional telomeres and/or induce replicative stress at telomeres to inhibit escape from a telomere crisis. This is the first demonstration that a drug can selectively kill cells experiencing telomeric crisis. We propose that this type of drug, which we term 'crisolytic', has the potential to eliminate pre-cancerous lesions and tumours exhibiting short dysfunctional telomeres.

AB - Telomeric crisis is the final replicative barrier to cell immortalisation; it is characterised by genome instability and cell death and is triggered when telomeres become critically short and are subjected to fusion. Pre-cancerous lesions, or early stage cancers, often show signs of a telomere crisis, suggesting that escape from telomere crisis is a prerequisite for disease progression. Telomeric crisis therefore represents an attractive, and as yet unexplored, opportunity for therapeutic intervention. Here, we show that two clinically approved PARP inhibitors, selectively eliminate human cells undergoing a telomere-driven crisis. Clonal populations of a colorectal cancer cell line (HCT116), or the plasma cell leukaemia cell line (JJN- 3), expressing a dominant-negative telomerase, entered a telomere-driven crisis at defined population doubling points and telomere lengths. The addition of the PARP inhibitors, olaparib or rucaparib prevented these cells from escaping crisis. PARP inhibition did not alter cellular proliferation prior to crisis, rates of telomere erosion or the telomere length at which crisis was initiated, but affected repair of eroded telomeres, resulting in an increased in intra-chromosomal telomere fusion. This was accompanied by enhanced DNA damage checkpoint activation and elevated levels of apoptosis. We propose that PARP inhibitors impair the repair of dysfunctional telomeres and/or induce replicative stress at telomeres to inhibit escape from a telomere crisis. This is the first demonstration that a drug can selectively kill cells experiencing telomeric crisis. We propose that this type of drug, which we term 'crisolytic', has the potential to eliminate pre-cancerous lesions and tumours exhibiting short dysfunctional telomeres.

KW - Cancer

KW - Crisis

KW - Genome instability

KW - PARP1

KW - Telomere

UR - http://www.scopus.com/inward/record.url?scp=85059173184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059173184&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85059173184

VL - 9

SP - 37549

EP - 37563

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 101

ER -